Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

Rivaroxaban and dabigatran are new oral anticoagulants that specifically inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment of venous and arterial thromboembolism show promising results. A major disadvantage of these anticoagulants is the absence of an ant...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Circulation (New York, N.Y.) Ročník 124; číslo 14; s. 1573
Hlavní autoři:	Eerenberg, Elise S, Kamphuisen, Pieter W, Sijpkens, Meertien K, Meijers, Joost C, Buller, Harry R, Levi, Marcel
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States 04.10.2011
Témata:	Adult Anticoagulants - antagonists & inhibitors Antidotes - pharmacology Benzimidazoles - antagonists & inhibitors beta-Alanine - analogs & derivatives beta-Alanine - antagonists & inhibitors Blood Coagulation - drug effects Blood Coagulation Factors - pharmacology Cross-Over Studies Dabigatran Double-Blind Method Endopeptidases Factor Xa Inhibitors Humans Male Morpholines - antagonists & inhibitors Partial Thromboplastin Time Prothrombin Time Rivaroxaban Thiophenes - antagonists & inhibitors Thrombin - antagonists & inhibitors Thrombin Time Young Adult
ISSN:	1524-4539, 1524-4539
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!